The Dark Side of Mast Cell–Targeted Therapy in Prostate Cancer

作者: Paola Pittoni , Mario Paolo Colombo

DOI: 10.1158/0008-5472.CAN-11-3110

关键词: Proinflammatory cytokineDiseaseImmunologyStem cell factorMedicineProstate cancerProstateTargeted therapyNeuroendocrine tumorsMast cell

摘要: Tumor development requires accomplices among white blood cells. Other than macrophages, mast cells have been observed to support the outgrowth of certain neoplasias because their proangiogenic properties. In some tumor settings, however, may a protective role, exerted by proinflammatory mediators. prostate cancer, no conclusive data on cell function were available. Here, we discuss recent work role in mouse and human showing that can behave alternatively as dangerous promoters, innocent bystanders, or essential guardians tumors, according stage origin transformed particular, are for early-stage tumors due matrix metalloproteinase–9 production, become dispensable advanced-stage, post–epithelial-to-mesenchymal transition, against neuroendocrine variants. The common expression c-Kit clones suggests possible competition ligand Stem factor offers chance curing disease while preventing using c-Kit–targeted therapy. This review discusses implications these findings advocated cell–targeted cancer therapy considers future directions study interactions with other c-Kit–expressing Cancer Res; 72(4); 831–5. ©2012 AACR.

参考文章(33)
Christoph Wiesner, Sanaa M. Nabha, R. Daniel Bonfil, Emanuel Burck Dos Santos, Hamilto Yamamoto, Hong Meng, Sebastian W. Melchior, Fernando Bittinger, Joachim W. Thüroff, Robert L. Vessella, Michael L. Cher, C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia. ,vol. 10, pp. 996- 1003 ,(2008) , 10.1593/NEO.08618
Enrico Crivellato, Carlo Alberto Beltrami, Franco Mallardi, Domenico Ribatti, Paul Ehrlich’s Doctoral Thesis: A Milestone in the Study of Mast Cells British Journal of Haematology. ,vol. 123, pp. 19- 21 ,(2003) , 10.1046/J.1365-2141.2003.04573.X
Naotomo Kanbe, Akane Tanaka, Michiyo Kanbe, Atsuko Itakura, Motohiro Kurosawa, Hiroshi Matsuda, Human mast cells produce matrix metalloproteinase 9. European Journal of Immunology. ,vol. 29, pp. 2645- 2649 ,(1999) , 10.1002/(SICI)1521-4141(199908)29:08<2645::AID-IMMU2645>3.0.CO;2-1
Anna Johansson, Stina Rudolfsson, Peter Hammarsten, Sofia Halin, Kristian Pietras, Jonathan Jones, Pär Stattin, Lars Egevad, Torvald Granfors, Pernilla Wikström, Anders Bergh, Mast Cells Are Novel Independent Prognostic Markers in Prostate Cancer and Represent a Target for Therapy American Journal of Pathology. ,vol. 177, pp. 1031- 1041 ,(2010) , 10.2353/AJPATH.2010.100070
Lisa M Coussens, Barbara Fingleton, Lynn M Matrisian, Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations Science. ,vol. 295, pp. 2387- 2392 ,(2002) , 10.1126/SCIENCE.1067100
Magda Babina, Claudia Rex, Sven Guhl, Friedrich Thienemann, Metin Artuc, Beate M. Henz, Torsten Zuberbier, Baseline and stimulated turnover of cell surface c‐Kit expression in different types of human mast cells Experimental Dermatology. ,vol. 15, pp. 530- 537 ,(2006) , 10.1111/J.1600-0625.2006.00446.X
Laurence Zitvogel, Guido Kroemer, Anticancer effects of imatinib via immunostimulation Nature Medicine. ,vol. 17, pp. 1050- 1051 ,(2011) , 10.1038/NM.2429
Bo Huang, Zhang Lei, Gui-Mei Zhang, Dong Li, Chuanwang Song, Bo Li, Yanyan Liu, Ye Yuan, Jay Unkeless, Huabao Xiong, Zuo-Hua Feng, SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment Blood. ,vol. 112, pp. 1269- 1279 ,(2008) , 10.1182/BLOOD-2008-03-147033